MILTENYI BIOTEC GMBH

Their core work

Miltenyi Biotec is a global biotech company specializing in cell separation, cell therapy manufacturing, and flow cytometry instruments and reagents. In H2020, they contribute proprietary cell isolation and processing technologies — particularly magnetic-activated cell sorting (MACS) — to projects developing advanced therapy medicinal products (ATMPs) including CAR-T and NK cell therapies. They serve as the industrial technology provider enabling GMP-grade cell manufacturing, automation, and quality control for translational immunotherapy research. Their tools and reagents are essential infrastructure for moving cell therapies from bench to bedside.

What they specialise in

How they've shifted over time

In their early H2020 period (2015-2018), Miltenyi focused squarely on CAR-T cell therapy — cell isolation, GMP manufacturing, automation, and regulatory compliance for advanced therapies, anchored by the large CARAT and PROCROP projects. From 2018 onward, their scope broadened: NK cell immunotherapy (MATURE-NK), organ-on-a-chip platforms (EUROoC), RNA therapeutics (TRAIN-HEART), and nanotechnology-based biosafety (ENDONANO) entered the picture. This signals a deliberate expansion from being a CAR-T manufacturing partner toward becoming a broader platform provider for multiple advanced therapy and preclinical testing modalities.

Miltenyi is expanding from cell therapy manufacturing into adjacent areas like organ-on-a-chip and biosafety nanotechnology, positioning itself as a versatile biotech platform provider rather than a single-therapy specialist.

How they like to work

Miltenyi consistently participates as a specialist partner — never as coordinator across all 11 projects. This reflects their role as an industrial technology supplier: they bring proprietary instruments and reagents to academic-led consortia rather than driving the research agenda. With 106 unique partners across 18 countries, they connect broadly rather than repeatedly with the same groups, making them a well-networked but non-exclusive partner available to diverse research teams.

Miltenyi has collaborated with 106 unique partners across 18 countries, reflecting extensive pan-European connections in the cell therapy and immunotherapy research community. Their network spans universities, hospitals, and biotech companies, with no apparent geographic concentration beyond their German base.

What sets them apart

Miltenyi Biotec is one of the few large biotech companies that provides end-to-end cell processing technology — from initial cell isolation through GMP-grade manufacturing — as a commercial product line rather than as a research-only capability. For consortium builders, they bring not just expertise but actual market-ready instruments and validated protocols, meaning project results can transition to clinical application faster. Their willingness to join as a specialist partner across many different therapeutic areas makes them an accessible and experienced industrial collaborator.

Highlights from their portfolio

• PROCROP
  Largest single project by EC funding (EUR 1.35M), focused on cross-priming immunotherapy for ovarian and prostate cancer — a clinically ambitious target.
• CARAT
  Second-largest funding (EUR 1.18M) and the most keyword-rich project, covering the full CAR-T value chain from cell isolation to GMP manufacturing and regulatory compliance.
• EUROoC
  Represents Miltenyi's strategic expansion into organ-on-a-chip technology — a departure from their traditional cell therapy focus, signaling new market directions.